Pancreatic cancer vaccine shows promise

The experimental vaccine works by teaching the patient's immune system to recognize and attack specific proteins found on their tumor cells.

Researchers at Memorial Sloan Kettering have hailed the findings as a major breakthrough, noting that pancreatic cancer has historically been resistant to most forms of immunotherapy.

While the trial was small, the long-term survival rates have sparked hope for a new era in personalized oncology.

Larger trials are currently underway to confirm the results and determine if the vaccine can be used alongside traditional treatments.